Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.
Message: IR Q&A
Many companies are able to give contract announcements with figures, revenue projections, and earnings guidance in upcoming quarters. Aside from the joint venture with TPL, will PTSC have the ability to provide any of the forementioned items in order to provide greater investment visibility to the public? I feel these items will provide traction to the share price over time.
Some companies choose to provide guidance because they have fairly good visibility into their financial future, and have the requisite volume of business that allows for a certain amount of margin of error in one area or another. Others choose to give only annual guidance so that lumpy revenue or expense items won't result in missing results for a quarter that might impact the stock price. Still others have chosen to give no guidance at all. We hope that the information we do provide about our strategy and progress in implementing that strategy will be useful to you. As a growth company, our financials can be greatly impacted by any level of unusual activity, and that does not lend itself well to providing earnings guidance that we could miss in either direction.
Secondly, regarding the licensing of PTSC's IP (ie:NuPower), is it the intention of PTSC to use TPL or not, in those licensing efforts?
Regarding your second question, Patriot has the option whether or not to engage TPL as the licensing agent for activity outside the MMP portfolio. It has not publicly announced its intention at this time.
5 Recommendations
Loading...
Loading...
New Message
Please
login
to post a reply